Ajanta Pharma's stock saw a rise following Motilal Oswal's positive outlook, driven by the company's new weight-loss drug, semaglutide. The brokerage anticipates significant gains from this partnership, projecting annual sales of $25-30 million from the drug in Asia and Africa by FY28. Motilal Oswal reiterated a 'buy' rating with a target price of Rs 3,145, suggesting a 17% upside, and expects Ajanta Pharma's revenue and profit to grow annually over FY26-28.